(olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority …

0%) and back pain (1% vs. 2%). AEs led to dose interruptions in 22% of patients on LYNPARZA vs. 4% of patients on abiraterone and enzalutamide …
Source: back pain